Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy

https://doi.org/10.1016/0002-9343(91)90066-7Get rights and content

Abstract

purpose: The impact of long-term L-thyroxine replacement therapy on skeletal integrity is a growing concern because of the large number of women receiving thyroid hormone therapy. The purpose of this study was to examine the hypothesis that long-term L-thyroxine therapy in which the free thyroxine index (FT4I) is maintained within a physiologic range has minimal impact on vertebral or femoral bone mineral density in both premenopausal and postmenopausel women.

patients and methods: We measured hip integral and spinal trabecular and integral bone densities in 28 premenopausal and 28 postmenopausal women who had been receiving L-thyroxine therapy for a median of 12 and 15 years, respectively, and in whom therapy was titrated to keep the FT4I within the normal range. The relationship between bone density parameters and thyroid hormone status was examined using univariate and multivariate statistical methods.

results: Seventy-nine percent of the premenopausal women and 86% of the postmenopausal women had FT4I values in the normal range at the time of bone density determination. Moreover, throughout the study's duration, the majority of annually measured values were in the normal range for more than 80% of subjects. Premenopausal women had slightly lower bone density than would be expected for age: −6.7% (z = −0.39 ± 0.74 [mean ±SD], p <0.01), −3.1% (z = −0.22 ± 0.78, p = 0.15), and −5.1% (z = −0.36± 0.74, p <0.02) for spinal trabecular, spinal integral, and hip integral bone density, respectively. Postmenopausal women likewise had slightly lower bone density values that were significant only at the hip: −0.2% (z = −0.01 ± 1.01, p = 0.95), −1.0% (z = −0.05 ±1.11, p = 0.80), and −6.2% (z = −0.39 ± 0.80, p <0.02) for spinal trabecular, spinal integral, and hip integral bone density, respectively. When patients with previously treated Graves' disease (n = 4 in each group) were eliminated, the differences in bone density at the hip were no longer seen. Correlation analysis revealed only weak and generally nonsignificant relationships between parameters of thyroid hormone status and bone density at any site in either subgroup. Results of multiple regression analysis among the pooled data of all subjects showed that age provided a consistently significant contribution (R2 = 0.18 to 0.66) to the variability in bone density at the spine and the hip, but parameters of thyroid hormone status did not.

conclusion: These data provide the first supportive evidence that long-term L-thyroxine therapy that maintains the FT4I in the physiologic range is associated with a statistically significant, but clinically minimal, decrement in spinal and hip bone density in both premenopausal and postmenopausal women. The decrement at the hip was entirely due to the inclusion of patients with treated Graves' disease. Thus, the changes in bone density in women receiving long-term L-thyroxine therapy are minimal at most and should not be a contraindication to therapy.

References (29)

  • JE Block et al.

    Models of spinal trabecular bone loss as determined by QCT

    J Bone Min Res

    (1989)
  • Heuch A; Block JE; Glueer CC, et al: Vertebral osteoporosis: statistical discrimination using bone densitometry...
  • G Benker et al.

    Calcium metabolism in thyroid disease

    J Endocrinol Invest

    (1988)
  • L Mosekilde et al.

    Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calciumphosphorous metabolism

    Acta Endocrinol (Copenh)

    (1977)
  • Cited by (112)

    • Bone geometry in older adults with subclinical hypothyroidism upon levothyroxine therapy: A nested study within a randomized placebo controlled trial

      2022, Bone
      Citation Excerpt :

      Compared with DXA, assessment of bone geometry by pQCT allows accurate determination of the specific effect of LT4 on cortical and trabecular bone, the volumetric density of these compartments, and changes in internal and external bone circumference. So far, only little is known about the effect of TSH on bone geometry and vBMD: TSH-Suppressive LT4-Treatment in patients with thyroidectomy may leads to detrimental effects on appendicular bone [23], but long-term LT4-treatment within physiological limits seems to only minimally influence areal bone density [24]. High TSH levels have been shown to increase the risk for fractures [9] and to decrease cortical [10] rather than trabecular bone, and may impact bone quality.

    • Thyroid Hormone and the Skeleton

      2013, Osteoporosis: Fourth Edition
    • Long-term treatment with supraphysiological doses of thyroid hormone in affective disorders - Effects on bone mineral density

      2012, Journal of Affective Disorders
      Citation Excerpt :

      One concern about long-term treatment with thyroid hormone, as required in prophylaxis, is a potentially increased risk of bone mineral density (BMD) loss (Biondi and Cooper, 2010; Mosekilde et al., 1990). The potential adverse effects of TSDL on skeletal integrity are unclear (Greenspan and Greenspan, 1999; Greenspan et al., 1991; Schneider and Reiners, 2003). As reviewed recently by Biondi and Cooper (2010) the literature does not show that TSDL due to differentiated thyroid cancer causes a decrease in BMD in males as well as premenopausal women.

    • Bone loss and fracture risk in thyroid diseases

      2011, Revue du Rhumatisme Monographies
    View all citing articles on Scopus

    This study was supported in part by a Physician-Scientist Award to Dr. S. Greenspan and an Academic Award to Dr. Resnick from the National Institute on Aging, and grants from the Radiology Research and Education Foundation, and Various Donors Fund of the Department of Medicine, University of California, San Francisco.

    View full text